Trial
NCT04044209
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Yale University
Collaborators
—
Condition
Myelodysplastic Syndromes
Intervention
AG-120
Why stopped
No patients were able to be screened nor enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-20